Scribe Therapeutics engineers CRISPR-based therapeutics to modify genetic predispositions, specifically targeting cardiometabolic diseases. By creating safe and effective gene-editing solutions, the company aims to empower individuals to take control of their health outcomes rather than being limited by inherited conditions.
Funding
$120.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PTFounders
Product
Problem
Cardiometabolic diseases, the leading cause of death globally, are often influenced by genetic predispositions that limit an individual's control over their health outcomes. Traditional treatment approaches address symptoms rather than the underlying genetic causes of these conditions. Current gene-editing technologies may lack the precision and safety required for widespread therapeutic application.
Solution
Scribe Therapeutics is developing CRISPR-based therapeutics designed to precisely and safely modify genetic predispositions associated with cardiometabolic diseases. The company employs a comprehensive molecular engineering approach to create CRISPR systems with enhanced safety and specificity. By targeting the root genetic causes, Scribe aims to prevent disease onset and liberate individuals from inherited conditions and lifetime treatments. Their engineered CRISPR medicines are designed to be safe and effective enough for widespread use, extending beyond rare diseases to address common health challenges.
Target Audience
The primary target audience includes individuals at risk of or affected by cardiometabolic diseases with a genetic component, as well as pharmaceutical companies seeking strategic collaborations in gene editing.
Features
- Purpose-built CRISPR-based therapeutics engineered for safety and potency.
- Comprehensive molecular engineering approach involving small, iterative steps.
- Focus on preventing common diseases by calibrating the genome.
- Potential to eliminate inherited conditions and lifetime treatment.
- Application of CRISPR technology to address the leading cause of death globally: cardiometabolic disease.
- Development of ex vivo NK cell therapies for oncology.
- Programs targeting SCD and other genetic diseases, as well as neuromuscular and neurologic diseases.